search

Active clinical trials for "Multiple Myeloma"

Results 3031-3040 of 3165

Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or...

Chronic Myeloproliferative DisordersKidney Cancer10 more

RATIONALE: Light-emitting diode (LED) therapy may be able to prevent mucositis of the mouth. PURPOSE: Randomized phase II trial to determine the effectiveness of LED therapy in preventing mucositis of the mouth in children who are receiving chemotherapy with or without radiation therapy before donor bone marrow transplantation.

Unknown status36 enrollment criteria

Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer...

AnemiaLeukemia4 more

RATIONALE: Epoetin alfa and epoetin beta may cause the body to make more red blood cells. Red blood cells contain iron that is needed to carry oxygen to the tissues. It is not yet known whether epoetin alfa or epoetin beta are more effective when given with or without iron infusion in treating anemia in patients with cancer. PURPOSE: This randomized phase III trial is studying epoetin alfa or epoetin beta to compare how well they work with or without iron infusion in treating anemia in patients with cancer.

Unknown status23 enrollment criteria

Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer

Chronic Myeloproliferative DisordersDrug/Agent Toxicity by Tissue/Organ7 more

RATIONALE: Drugs used in chemotherapy use different ways to stop tumors from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy. PURPOSE: Phase I trial to study the effectiveness of amifostine plus combination chemotherapy in treating patients with advanced cancer.

Unknown status3 enrollment criteria

Observational Study of Home Administration of Carfilzomib

Multiple MyelomaHematologic Diseases

The purpose of this study is to evaluate the feasibility of an at home administration program for carfilzomib patients.

Withdrawn11 enrollment criteria

Prevalence of Asymptomatic Thrombosis in Multiple Myeloma

ThrombosisMultiple Myeloma

Malignant hemopathies, such as solid cancers, increase the risk of venous and arterial thromboembolic events. The incidence of symptomatic venous thromboembolic events is particularly high in myeloma, linked to the usual risk factors for venous thromboembolic disease, biological risk factors specific to myeloma, and especially to its treatments. The prevalence of asymptomatic venous thromboembolic events and arterial events are not known to date and remain important data for planning a possible randomized study to determine the most suitable thromboprophylaxis in these patients.

Withdrawn11 enrollment criteria

Perceptions of Burden in Patients With Late-Stage Cancer and Their Caregivers

Brain and Central Nervous System TumorsChronic Myeloproliferative Disorders9 more

RATIONALE: Gathering information over time about patients' sense of being a burden on their caregiver, and caregivers' sense of burden on themselves, may help doctors learn more about the desire to die in patients with late-stage cancer. PURPOSE: This clinical trial is studying perceptions of burden in patients with late-stage cancer and their caregivers.

Withdrawn14 enrollment criteria

Collecting and Storing Blood Samples From Patients With Cancer

Brain and Central Nervous System TumorsChronic Myeloproliferative Disorders11 more

RATIONALE: Collecting and storing samples of blood from patients with cancer to test in the laboratory may help the study of cancer in the future. PURPOSE: This research study is collecting and storing blood samples from patients with cancer.

Withdrawn7 enrollment criteria

A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed...

Multiple Myeloma

This study is to understand how well elranatamab (PF-06863135) may be used for relapsed refractory multiple myeloma (RRMM). Sometimes MM might improve at first, but then gets resistant to the treatment and starts growing again (known as relapsed refractory). This study medicine will be compared with standard-of-care (SOC) therapies used in real-world clinical practice. For people receiving elranatamab, the investigators will use data from the phase 2 clinical trial (MagnetisMM-3). The investigators will also use data from multiple real-world sources, representing the SOC in clinical practice. This study does not seek any participants for enrollment. The investigators will compare the experiences of people receiving elranatamab to people receiving SOC therapies. This way, it will help the investigators to know how well elranatamab can be used for RRMM treatment.

Completed12 enrollment criteria

Clinical and Sociodemographic Characterization of Multiple Myeloma Participants With Symptomatic...

Multiple Myeloma

The purpose of this study is to characterize the multiple myeloma (MM) participants with symptomatic relapse and/or refractory disease in Spain.

Completed6 enrollment criteria

Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy

Acute Myelogenous LeukemiaMultiple Myeloma5 more

This is a prospective, multicenter observational study to collect clinically annotated biospecimens in order to assess the correlation between ex vivo data generated by the Notable assay platform and clinical outcome.

Completed21 enrollment criteria
1...303304305...317

Need Help? Contact our team!


We'll reach out to this number within 24 hrs